ARID1A and ovarian serous adenocarcinoma: Additionally, the combination of AZD6738 (ATR inhibitor) and olaparib (inhibitor of PARP (Poly ADP-ribose polymerase)) reduced tumor burden in BRCA-mutant high grade serous ovarian cancer [70] although other study showed ARID1A loss is associated with PARP inhibitor resistance [71].